EyePoint Pharmaceuticals, Inc.

NasdaqGM:EYPT Stock Report

Market Cap: US$542.3m

EyePoint Pharmaceuticals Valuation

Is EYPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EYPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$23.02
Fair Value
65.0% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: EYPT ($8.05) is trading below our estimate of fair value ($23.02)

Significantly Below Fair Value: EYPT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EYPT?

Key metric: As EYPT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EYPT. This is calculated by dividing EYPT's market cap by their current revenue.
What is EYPT's PS Ratio?
PS Ratio12.4x
SalesUS$45.71m
Market CapUS$542.34m

Price to Sales Ratio vs Peers

How does EYPT's PS Ratio compare to its peers?

The above table shows the PS ratio for EYPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
SIGA SIGA Technologies
2.6x7.5%US$442.7m
TBPH Theravance Biopharma
7.5x24.4%US$473.5m
ZVRA Zevra Therapeutics
17.5x39.4%US$419.5m
PAHC Phibro Animal Health
0.8x12.5%US$890.5m
EYPT EyePoint Pharmaceuticals
12.4x49.0%US$542.3m

Price-To-Sales vs Peers: EYPT is expensive based on its Price-To-Sales Ratio (12.4x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does EYPT's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

68 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
0.9x-1.3%US$13.52b
OGN Organon
0.6x0.5%US$4.08b
PRGO Perrigo
0.8x3.7%US$3.37b
BHC Bausch Health Companies
0.3x0.6%US$2.75b
EYPT 12.4xIndustry Avg. 3.2xNo. of Companies68PS048121620+
68 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: EYPT is expensive based on its Price-To-Sales Ratio (12.4x) compared to the US Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is EYPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EYPT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.4x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: EYPT is expensive based on its Price-To-Sales Ratio (12.4x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EYPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.05
US$33.42
+315.1%
41.8%US$68.00US$18.00n/a12
Jan ’26US$7.45
US$33.45
+349.1%
43.6%US$68.00US$18.00n/a11
Dec ’25US$8.85
US$33.45
+278.0%
43.6%US$68.00US$18.00n/a11
Nov ’25US$12.06
US$36.18
+200.0%
36.3%US$68.00US$18.00n/a11
Oct ’25US$8.00
US$36.64
+358.0%
36.1%US$68.00US$15.00n/a11
Sep ’25US$8.95
US$36.64
+309.3%
36.1%US$68.00US$15.00n/a11
Aug ’25US$9.13
US$38.44
+321.1%
31.6%US$68.00US$28.00n/a9
Jul ’25US$8.31
US$38.44
+362.6%
31.6%US$68.00US$28.00n/a9
Jun ’25US$10.71
US$38.78
+262.1%
30.9%US$68.00US$28.00n/a9
May ’25US$18.04
US$43.89
+143.3%
23.8%US$68.00US$33.00n/a9
Apr ’25US$20.27
US$43.89
+116.5%
23.8%US$68.00US$33.00n/a9
Mar ’25US$28.00
US$43.33
+54.8%
25.5%US$68.00US$30.00n/a9
Feb ’25US$28.51
US$41.67
+46.1%
27.6%US$68.00US$30.00n/a9
Jan ’25US$23.11
US$42.75
+85.0%
27.4%US$68.00US$30.00US$7.458
Dec ’24US$6.61
US$30.75
+365.2%
32.9%US$55.00US$20.00US$8.858
Nov ’24US$7.24
US$31.00
+328.2%
32.3%US$55.00US$20.00US$12.068
Oct ’24US$7.99
US$32.57
+307.7%
29.9%US$55.00US$22.00US$8.007
Sep ’24US$10.52
US$32.57
+209.6%
29.9%US$55.00US$22.00US$8.957
Aug ’24US$12.70
US$32.57
+156.5%
29.9%US$55.00US$22.00US$9.137
Jul ’24US$8.70
US$32.57
+274.4%
29.9%US$55.00US$22.00US$8.317
Jun ’24US$5.96
US$32.57
+446.5%
29.9%US$55.00US$22.00US$10.717
May ’24US$6.64
US$32.43
+388.4%
28.2%US$52.00US$21.00US$18.047
Apr ’24US$2.94
US$32.33
+999.8%
30.5%US$52.00US$21.00US$20.276
Mar ’24US$3.17
US$32.33
+920.0%
30.5%US$52.00US$21.00US$28.006
Feb ’24US$4.75
US$32.33
+580.7%
30.5%US$52.00US$21.00US$28.516
Jan ’24US$3.50
US$32.33
+823.8%
30.5%US$52.00US$21.00US$23.116
Analyst Price Target
Consensus Narrative from 12 Analysts
US$33.42
Fair Value
75.9% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:53
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EyePoint Pharmaceuticals, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Andrew D'SilvaB. Riley Securities, Inc.
Jennifer KimCantor Fitzgerald & Co.